Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

MeDiSyn Scalable Microbial Metabolite Discovery Through Synthetic Biology

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 January 2024 to 31 December 2028
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101117891

What the project is doing

In the project's own words, from its summary on CORDIS.

The discoveries of microbial secondary metabolites (SM) led to an incalculable impact on human health and lifespan. A large share of the antibiotics, anticancers and immunosuppressants in use today originate from microorganisms. However, discoveries of SMs of microbial origin through traditional approaches have declined in the past decades, depriving drug pipelines from a key source of bioactive molecules. The consequences are dire, in particular in the case of antibiotics.

Encouragingly, the study of the biosynthetic genes responsible for the synthesis of SMs indicates that the natural repertoire remains vastly underexplored, and new ways to access it are enabled by DNA technologies. In particular, untapped biosynthetic genes can be interrogated by transferring them into heterologous hosts. I am developing a method for transfer which fulfils the conditions to unleash theoretically massive economies of scale.

Here I propose to multiply the scalability of the current heterologous expression framework and effectively overcome the diminishing returns faced by traditional approaches. In the first axis, I will implement a full-fledged discovery platform, optimized to systematically interrogate novel biosynthetic gene clusters identified bioinformatically from a large collection of soil bacteria. Second, the scale and parallel nature of the heterologous expression setup will be used to better understand the logic of activation of biosynthetic genes, and identify optimal ways to increase activation rates among the large reservoir of conditionally silent biosynthetic genes.

Finally, the general strategy will be extended to new fungal and bacterial clades to enable interrogation of their vast potential through scalable heterologous expression. Overall, this proposal aims at developing heterologous expression into a major way to discover microbial secondary metabolites and drug leads.

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI